



ELSEVIER



# REVISTA DE GASTROENTEROLOGÍA DE MÉXICO

[www.elsevier.es/rgrm](http://www.elsevier.es/rgrm)



## BRIEF COMMUNICATION

### Increase in Mexican and Latin American scientific articles on irritable bowel syndrome<sup>☆</sup>



R. Porras<sup>a</sup>, A. López-Colombo<sup>b</sup>, M. Schmulson<sup>a,\*</sup>

<sup>a</sup> Laboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Hospital General de México, Mexico City, Mexico

<sup>b</sup> Dirección de Educación e Investigación en Salud, Unidad Médica de Alta Especialidad (UMAE), Hospital de Especialidades Centro Médico Nacional Manuel Ávila Camacho, Instituto Mexicano del Seguro Social (IMSS), Puebla de Zaragoza, Puebla, Mexico

Received 6 May 2015; accepted 11 June 2015

Available online 11 September 2015

#### KEYWORDS

Irritable bowel syndrome;  
Epidemiology;  
Mexico;  
Latin America;  
Research;  
Articles

#### Abstract

**Background:** There is an implied perception that little scientific information on irritable bowel syndrome (IBS) comes out of Mexico and Latin America in the international medical literature, but the number and tendencies of articles from the region on IBS are not known.

**Aims:** To determine the number and type of Mexican and Latin American articles on IBS published between 1990–2015.

**Methods:** A systematic search of Medline was carried out employing the terms «Irritable Bowel Syndrome» or its abbreviation (IBS). Mexico and every other Latin American country were added to specify the search. The articles were selected if they were published in Mexico and/or the rest of Latin America, if they were international papers on IBS in the region, or if they were written by Mexican and/or Latin American authors. In addition, the articles were classified into the following categories: Review Articles/Editorials/Letters to the Editor (REV/ED), studies emphasizing aspects of Epidemiology/Quality of Life/Psychosocial Factors (EPI/QOL), articles dealing with Diagnoses (DX), with Treatment (TX), and Translational/Pathophysiologic studies (TRANS).

**Results:** A total of 66 articles from Mexico and 47 from Latin America were identified, but only 87.7 and 48.9%, respectively, fit the selection criteria. Category distribution was: EPI/QOL: 36.2%, REV/ED: 27.5%, TRANS: 18.8, TX: 10%, and DX: 7.5% and was similar between Mexico

<sup>☆</sup> Please cite this article as: Porras R, López-Colombo A, Schmulson M. Incremento en las publicaciones científicas sobre síndrome de intestino irritable en México y Latinoamérica. Revista de Gastroenterología de México. 2015;80:228–235.

\* Corresponding author. Laboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Hospital General de México, Dr. Balmis #148, Col. Doctores C.P. 06726, México D.F. México. Tel.: +52 5556232673; fax: +52 5556232669.

E-mail address: [maxjulio@prodigy.net.mx](mailto:maxjulio@prodigy.net.mx) (M. Schmulson).

and Latin America ( $p=0.33$ ). The year 2005 saw an increase in the number of articles in Mexico, with a peak in 2010. The figures for Latin American articles remained stable over the years, with a peak in 2012.

**Conclusions:** A noticeable increase has been observed over the last decade in the research conducted on IBS in Mexico and Latin America. Even though the EPI/QOL studies predominate, the sophistication of research is reflected in the TRANS studies that are in third place of frequency. The information referred to herein demonstrates maturity in the field, making it possible to carry out consensuses based on local data.

© 2015 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## PALABRAS CLAVE

Síndrome de intestino irritable;  
Epidemiología;  
México;  
Latinoamérica;  
Investigación;  
Artículos

## Incremento en las publicaciones científicas sobre síndrome de intestino irritable en México y Latinoamérica

### Resumen

**Antecedentes:** En la literatura internacional se crea la idea de que la información científica sobre el síndrome de intestino irritable (SII) en México y Latinoamérica es escasa. Sin embargo, se desconoce el número y la tendencia de las publicaciones sobre SII en la región.

**Objetivo:** Determinar el número y tipo de publicaciones sobre SII en México y Latinoamérica entre 1990-2015.

**Métodos:** Búsqueda sistemática en Medline empleando los términos «síndrome de intestino irritable» o su abreviatura (IBS) en inglés, cruzándolo con México y cada país de Latinoamérica. Los artículos se seleccionaron según hubieran sido publicados en México y/o Latinoamérica; publicaciones internacionales sobre SII en la región o por autores mexicanos y/o latinoamericanos. Además se clasificaron en categorías: Revisión/Editorial/Cartas al Editor (REV/ED), Epidemiología/Calidad de vida/Factores psicosociales (EPI/QOL), Diagnóstico (DX), Tratamiento (TX), Traslacional/Fisiopatología (TRAS).

**Resultados:** Se identificaron 66 publicaciones de México y 47 de Latinoamérica pero solo un 87.7% y un 48.9% respectivamente se ajustaron a los criterios de selección. La distribución de categorías fue: EPI/QOL, 36.2%; REV/ED, 27.5%; TRAS, 18.8%; TX, 10%; DX, 7.5%; similar entre México y Latinoamérica ( $p=0.33$ ). Las publicaciones se incrementaron a partir del 2005 con un pico en 2010 en México, y se mantuvieron estables a lo largo de los años con un pico en 2012 en Latinoamérica.

**Conclusión:** En la última década se observa un aumento notorio en la investigación sobre SII en México y Latinoamérica. Si bien predominan los estudios EPI/QOL, la sofisticación se refleja en los TRAS que ocupan el tercer lugar. Lo anterior demuestra una madurez que permite realizar consensos basados en datos locales.

© 2015 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

There is an implied perception of low scientific production in the field of functional gastrointestinal disorders, and especially irritable bowel syndrome (IBS), in Latin America. In fact, a systematic review of the medical literature on the overall prevalence of IBS based on open population studies concluded that there is a lack of studies on the prevalence and epidemiologic characteristics of this disorder, especially from Central America, and that there are few studies from South America.<sup>1</sup> The review only identified 4 South American articles, one of which was not really an open population study.<sup>2</sup> This is important, given that IBS has a reported incidence of 9-16%<sup>3</sup> and is among the 5 most frequent gastrointestinal disorders.<sup>4</sup>

Because our perception is that there is an increase in IBS research in the region, our aim was to carry out a search on Medline covering the last 25 years. Our hypothesis was that there has been an upsurge in the number of articles on IBS in Mexico and Latin America.

## Methods

A search was carried out on Medline encompassing the time frame of January 1, 1990 to April 1, 2015. Due to our specific interest, Mexico and Latin America were searched separately. The terms “*Irritable Bowel Syndrome*” or “*IBS*” were used, matching them with “*Mexico*” or “*Latin America*”. Because no result was found with “*Latin America*”,

the search was repeated with the names of each of the Latin American countries. Two of the present authors (RP, MS) individually reviewed the abstracts of each of the identified articles, and when necessary, the complete article, to corroborate that they met the selection criteria. Said criteria were: 1) Articles on IBS published in Mexico and/or Latin America, and/or 2) International articles that referred to IBS in the region, and/or 3) Articles on IBS written by Mexican and/or Latin American authors. The same 2 authors then met to jointly decide which articles fit the selection criteria; they excluded articles that were not really about IBS, articles that were about IBS, but not from Mexico or Latin America, or articles that were not written by authors from the region. In addition, the articles were classified into 5 categories: Reviews/Editorials/Letters to the Editor (REV/ED), Epidemiology/Quality of Life/Psychosocial Factors (EPI/QOL), Diagnostic (DX), Treatment (TX), and Translational/Pathophysiologic (TRANS) studies. In the results, the articles are described by year, the country of the authors, and the corresponding categories. The frequency of the categories was compared between Mexico and Latin America. The mean number of articles was described per year. A graph was plotted with the number of articles per year to determine if there was an increase in the publications within the time frame of interest, separating Mexico from the rest of Latin America. The results were expressed as frequencies and the comparisons were made using the Fisher exact test. Statistical significance was set at a  $p < 0.05$ .

## Results

A total of 66 publications from Mexico and 47 from the rest of Latin America were identified. Of the former, 57 (87.7%) met the selection criteria, and of the latter, 23 (48.9%). Table 1 shows the articles according to the different categories in the following order of frequency: EPI/QOL, 36.2%; REV/ED, 27.5%; TRANS, 18.8%; TX, 10%; and DX, 7.5%. There were no differences in the categories between Mexico and Latin America: EPI/QOL, 42.1% vs 21.3%; REV/ED, 24.5% vs 34.8%; TRANS, 19.3% vs 17.4%; TX, 7.0% vs 17.4%; DX, 7.0% vs 8.7%;  $p = 0.33$ .

In Mexico approximately 3 articles/year were published on IBS, starting from 1997, whereas in the rest of Latin America 1.5/year were published starting from 2001. Furthermore, in 2005, there was an increase of 84.2% in the number of articles published in Mexico, reaching a peak in 2010 (fig. 1). In the rest of Latin America, even though the majority of articles (82.6%) were published starting from 2005, this remained stable through the years, with a peak in 2011. No references were found for 2014 (fig. 1).

## Discussion

In the present review using the Medline database, we identified an increase in publications on IBS in Mexico and the rest of Latin America, mainly from 2005-2010. Nevertheless, it should be noted that over twice as many articles were published in Mexico, compared with the other countries of the region. The most frequent articles were those related




Figure 1 Number of articles per year in Mexico and the rest of Latin America.

to epidemiologic aspects, quality of life, and psychosocial aspects.

Even though we identified an important number of articles on Medline, it should be mentioned that there is a publication bias in that database. For example, there are articles published in local journals with well conducted epidemiologic studies that are not cited. Such is the case of a Uruguayan study,<sup>5</sup> as well as a Venezuelan study,<sup>6</sup> on IBS prevalence. We also observed in the search that letters to the editor<sup>7</sup> and even recent editorials<sup>8</sup> on IBS published in journals that are referenced in Medline were not identified. Therefore in order to carry out an adequate review on IBS in Mexico and Latin America it is necessary to analyze other databases, such as BIREME/Lilacs or SciELO.

With respect to the categories of the articles, it was not surprising to find that the majority corresponded to epidemiologic studies and articles on quality of life and psychosocial factors, perhaps because they are the simplest to conduct and generally only require the application of questionnaires. On the other hand, grouping these 3 aspects into a single category can explain its greater number of articles. To our surprise, the translational and pathophysiologic articles that require specialized laboratory techniques and researchers, and that would have been thought to be less frequent, were third place in frequency. This indicates the ever-increasing sophistication of research in this field in Mexico and Latin America. It should also be mentioned that some of the review articles are collaborations between authors from Latin America and other parts of the world.<sup>9,10</sup> This suggests the growing importance and leadership at the international level of certain Latin American researchers in the field of IBS.

Finally, the higher scientific production in regard to IBS in Mexico than in the other Latin American countries should also be noted. This is most likely due to the fact that there are greater funding for research in Mexico, and especially the fact that those physicians and basic scientists in academia are gaining more recognition and better-paying jobs. Such resources appear to be scarcer in the other Latin American countries, and the effort that persons in those countries must make to carry out research and publish deserves to be recognized.

**Table 1** Mexican and Latin American articles on IBS according to categories.

Article	Country	Category
Awad RA, Martin J, Guevara M, Ramos R, Noguera JL, Camacho S, Santiago R, Ramirez JL, Toriz A. Defaecography in patients with irritable bowel syndrome and healthy volunteers. <i>Int J Colorectal Dis.</i> 1997;12:91-4.	Mexico	DX
Schmulson MW, Chang L. Diagnostic approach to the patient with irritable bowel syndrome. <i>Am J Med.</i> 1999;107:20S-26S.	Mexico/USA	REV/ED
Schmulson MJ. Brain-gut interaction in irritable bowel syndrome: new findings of a multicomponent disease model. <i>Isr Med Assoc J.</i> 2001;3:104-10.	Mexico	REV/ED
Campos Hurtado G, Villareal Menchola J, Cornejo Zapata C, León Barúa R. [Prevalence of Manning's symptoms in a Lima upper socioeconomic level population]. <i>Rev Gastroenterol Peru.</i> 2001;21:301-5.	Peru	EPI/QOL
Norman P. Tegaserod (Novartis). <i>IDrugs.</i> 2002;5:171-9.	UK	TX
Huerta I, Bonder A, López L, Ocampo MA, Schmulson M. [Differences in the stress symptoms rating scale in Spanish between patients with irritable bowel syndrome (IBS) and healthy controls]. <i>Rev Gastroenterol Mex.</i> 2002;67:161-5.	UK	EPI/QOL
Curioso WH, Donaires Mendoza N, Bacilio Zerpa C, Ganoza Gallardo C, León Barúa R. [Prevalence and relation of dyspepsia to irritable bowel syndrome in a native community of the Peruvian jungle]. <i>Rev Gastroenterol Peru.</i> 2002;22:129-40.	Peru	EPI/QOL
Zetina-López A, Custodio-Vázquez A, Hinojosa C, Juárez-Paiz L, Schmulson M. [Impact of gastrointestinal symptoms on health related quality of life in patients with type 2 diabetes mellitus]. <i>Rev Invest Clin.</i> 2003;55:594-9.	Mexico	EPI/QOL
Quera R, Valenzuela J. [Visceral hypersensitivity: a concept within our reach]. <i>Rev Med Chil.</i> 2003;131:85-92.	Chile	REV/ED
Gómez-Escudero O, Schmulson-Wasserman MJ, Valdovinos-Díaz MA. [Post-infectious irritable bowel syndrome. A review based on current evidence]. <i>Rev Gastroenterol Mex.</i> 2003;68:55-61.	Mexico	REV/ED
Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. <i>Am J Gastroenterol.</i> 2004;99:1774-8.	USA	EPI/QOL
Sánchez RC, Navarro Cano G. [Diagnostic value of limited research in patients with irritable bowel syndrome]. <i>Rev Gastroenterol Mex.</i> 2004;69:24-9.	Mexico	DX
Montes R, Monge E. Lactose malabsorption and IBS. <i>Scand J Gastroenterol.</i> 2004;39:1033;	Peru	REV/ED
Carmona-Sánchez R, Tostado-Fernández FA. [Prevalence of use of alternative and complementary medicine in patients with irritable bowel syndrome, functional dyspepsia and gastroesophageal reflux disease]. <i>Rev Gastroenterol Mex.</i> 2005;70:393-8.	Mexico	TX
Cornejo Zapata C, Villarreal Menchola J. [Relation between irritable bowel syndrome symptoms and depressive symptoms in hospitalized patients]. <i>Rev Gastroenterol Peru.</i> 2005;25:156-60.	Peru	EPI/QOL
Otero Regino W, Gómez Zuleta M. [Irritable bowel syndrome: a concise diagnostic and pharmacological therapy review]. <i>Rev Gastroenterol Peru.</i> 2005;25:189-97.	Colombia	REV/ED
Peláez-Luna M, Schmulson M, Robles-Díaz G. Intestinal involvement is not sufficient to explain hypertransaminasemia in celiac disease? <i>Med Hypotheses.</i> 2005;65:937-41.	Mexico	DX
Mangel AW. Postinfectious IBS. <i>Am J Gastroenterol.</i> 2005;100:729.	USA	EPI/QOL
Ariza JG, Martínez JA. [Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod]. <i>Rev gastroenterol Peru.</i> 2006;26:77-9.	Peru	TX
Leyva-Jiménez R, Olvera-Torres P, Alvarez-Córdova MM, Alcántar-Saldívar EL. [Irritable bowel syndrome in adults attending to medical offices at UMF]. <i>Rev Med Inst Mex Seguro Soc.</i> 2006;44:473-9.	Mexico	EPI/QOL
Schmulson MJ, Ortiz-Garrido OM, Hinojosa C, Arcila D. A single session of reassurance can acutely improve the self-perception of impairment in patients with IBS. <i>J Psychosom Res.</i> 2006;61:461-7.	Mexico	REV/ED
Schmulson M, Ortíz O, Santiago-Lomeli M, Gutiérrez-Reyes G, Gutiérrez-Ruiz MC, Robles-Díaz G, Morgan D. Frequency of functional bowel disorders among healthy volunteers in Mexico City. <i>Dig Dis.</i> 2006;2:342-7.	Mexico	EPI/QOL
Defilippi G C, Quera P R, Madrid S AM, Defilippi C C, Valenzuela E J. [Rectal barostat in irritable bowel syndrome]. <i>Rev Med Chil.</i> 2006;134:1524-9.	Chile	DX

**Table 1** (Continued)

Article	Country	Category
Awad RA, Camacho S, Martín J, Ríos N. Rectal sensation, pelvic floor function and symptom severity in Hispanic population with irritable bowel syndrome with constipation. <i>Colorectal Dis.</i> 2006;8:488-93.	Mexico	EPI/QOL
Remes-Troche JM, Adames K, Castillo-Rodal AI, Ramírez T, Barreto-Zuñiga R, López-Vidal Y, Uscanga LF. Intraepithelial gammadelta+ lymphocytes: a comparative study between celiac disease, small intestinal bacterial overgrowth, and irritable bowel syndrome. <i>J Clin Gastroenterol.</i> 2007;41:671-6.	Mexico	TRANS
Soifer LO, Iantorno G, Bustos Fernández LM, Soifer G, Dima G, Peralta D, Besasso H. [Breath hydrogen levels do not predict fiber intolerance in irritable bowel syndrome with constipation]. <i>Acta Gastroenterol Latinoam.</i> 2007;37:15-9	Argentina	TX
Madrid AM, Defilippi C C, Defilippi G C, Slimming A J, Quera P R. [Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases]. <i>Rev Med Chil.</i> 2007;135:1245-52.	Chile	TRANS
Schmulson M, Ortiz O, Mejia-Arangure JM, Hu YB, Morris C, Arcila D, Gutierrez-Reyes G, Bangdiwala S, Grossman DA. Further validation of the IBS-QOL: female Mexican IBS patients have poorer quality of life than females from North Carolina. <i>Dig Dis Sci.</i> 2007;52:2950-5.	Mexico	EPI/QOL
Schmulson MJ. [Limited diagnostic testing can decrease the direct economic impact of irritable bowel syndrome]. <i>Rev Med Chil.</i> 2008;136:1398-405.	Mexico	DX
de Medeiros MT, Carvalho AF, de Oliveira Lima JW, Dos Santos AA, de Oliveira RB, Nobre E Souza MA. Impact of depressive symptoms on visceral sensitivity among patients with different subtypes of irritable bowel syndrome. <i>J Nerv Ment Dis.</i> 2008;196:711-4.	Brazil	TRANS
Reséndiz-Figueroa FE, Ortiz-Garrido OM, Pulido D, Arcila-Martínez D, Schmulson M. [Impact of the anxiety characteristics and depression on clinical aspects and quality of life in patients with irritable bowel syndrome]. <i>Rev Gastroenterol Mex.</i> 2008;73:3-10.	Mexico	EPI/QOL
Remes-Troche JM, Carmona-Sánchez R, González-Gutiérrez M, Martínez-Salgado JC, Gómez-Escudero O, Ramírez A, Vázquez-Jiménez G, García-Leiva J, Abarca-Castrejon M, Roesch-Dietlen F. [What people mean by constipation? A general population based-study.]. <i>Rev Gastroenterol Mex.</i> 2009;74:321-8.	Mexico	EPI/QOL
Carmona-Sánchez R, Remes-Troche JM, Gómez-Escudero O, Icaza-Chávez ME, García-Leiva J. [Self-perception, colonic transit and characteristics of subjects seeking medical care for constipation in Mexico.]. <i>Rev Gastroenterol Mex.</i> 2009;74:187-94.	Mexico	EPI/QOL
Gómez Alvarez DF, Morales Vargas JG, Rojas Medina LM, Mújica Oviedo SC, Camacho López PA, Rueda Jaimes GE. [Prevalence of irritable bowel syndrome and associated factors according to the Rome III diagnostic criteria in a general population in Colombia]. <i>Gastroenterol Hepatol.</i> 2009;32:395-400.	Colombia	REV/ED
Schmulson M, Vargas JA, López-Colombo A, Remes-Troche JM, López-Alvarenga JC. [Prevalence and clinical characteristics of the IBS subtypes according to the Rome III criteria in patients from a clinical, multicentric trial. A report from the Mexican IBS Working Group]. <i>Rev Gastroenterol Mex.</i> 2010;75:427-38.	Mexico	EPI/QOL
Schmulson M, Adeyemo M, Gutiérrez-Reyes G, Charúa-Guindic L, Farfán-Labonne B, Ostrosky-Solis F, Díaz-Anzaldúa A, Medina L, Chang L. Differences in gastrointestinal symptoms according to gender in Rome II positive IBS and dyspepsia in a Latin American population. <i>Am J Gastroenterol.</i> 2010;105:925-32.	Mexico	EPI/QOL
Awad RA, Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. <i>Colorectal Dis.</i> 2010;12:1131-8.	Mexico	TX
Valerio-Ureña J, Vásquez-Fernández F, Jiménez-Pineda A, Cortázar-Benítez LF, Azamar-Jácome AA, Duarte- Velázquez ME, Torres-Medina V. [Prevalence of irritable bowel syndrome in Veracruz City, Mexico: a community-based survey]. <i>Rev Gastroenterol Mex.</i> 2010;75:36-41.	Mexico	EPI/QOL
Schmulson M, Pulido D, Escobar C, Farfán-Labone B, Gutiérrez-Reyes G, López-Alvarenga JC. Heartburn and other related symptoms are independent of body mass index in irritable bowel syndrome. <i>Rev Esp Enferm Dig.</i> 2010;102:229-33.	Mexico	EPI/QOL

**Table 1** (Continued)

Article	Country	Category
Camacho S, Bernal F, Abdo M, Awad RA. Endoscopic and symptoms analysis in Mexican patients with irritable Bowel syndrome, dyspepsia, and gastroesophageal reflux disease. <i>An Acad Bras Cienc.</i> 2010;82:953-62.	Mexico	EPI/QOL
Reyes-Huerta JU, de la Cruz-Patiño E, Ramírez-Gutiérrez de Velasco A, Zamudio C, Remes-Troche JM. [Fructose intolerance in patients with irritable bowel syndrome: a case-control study]. <i>Rev Gastroenterol Mex.</i> 2010;75:405.	Mexico	EPI/QOL
Rojas-Macías V, Rodríguez-Fandiño O, Jiménez-Ponce F, Saldivar-González JA, Melendro-Lozano E, López- Iwarenga JC, Raya-Santoyo SB, Santana-Vargas AD, Schmulson M. [External validity of a relevant model for Irritable Bowel Syndrome (IBS) using chronic stress by water avoidance in Wistar rats]. <i>Rev Gastroenterol Mex.</i> 2010;75:421-6.	Mexico	TRANS
Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. <i>J Neurogastroenterol Motil.</i> 2010;16:363-73.	Mexico	TRANS
Ramirez-Miranda ME, Hernandez-Castellanos R, Lopez-Escamilla E, Moncada D, Rodriguez-Magallan A, Pagaza-Melero C, Gonzalez-Angulo A, Flisser A, Kawa-Karasik S, Maravilla P. Parasites in Mexican patients with irritable bowel syndrome: a case-control study. <i>Parasit Vectors.</i> 2010;3:96.	Mexico	REV/ED
León-Barúa R. [Comments on irritable bowel syndrome]. <i>Rev Gastroenterol Peru.</i> 2010;30:52-4.	Peru	REV/ED
Becker-Dreps S, Morgan D, Peña R, Cortes L, Martin CF, Valladares E. Association between intimate partner violence and irritable bowel syndrome: a population-based study in Nicaragua. <i>Violence Against Women.</i> 2010;16:832-45.	USA	EPI/QOL
Ramírez-Miranda ME, Jiménez-González DE, Rodríguez-Campa ME, González-Angulo A, Hernández-Castellanos R, Sara Arroyo-Escalante A, Romero-Valdovinos M, Martínez-Hernández F, Flisser A, Maravilla P. [Irritable bowel syndrome: frequency and phylogenetic relationship of Blastocystis sp. from Mexican patients]. <i>Rev Gastroenterol Mex.</i> 2011;76:309-15.	Mexico	TRANS
Schmulson M, Chang L. Review article: the treatment of functional abdominal bloating and distension. <i>Aliment Pharmacol Ther.</i> 2011;33:1071-86	Mexico/USA	REV/ED
Fosado-Gayoso M, Casillas-Guzmán GB, Serralde-Zúñiga AE, Pérez-Hernández JL, Higuera-de la Tijera MF, Pérez-Torres E, Abdo-Francis JM. [Association between anxiety and quality of life in different subgroups irritable bowel syndrome]. <i>Rev Gastroenterol Mex.</i> 2011;76.	Mexico	EPI/QOL
Arévalo F, Aragon V, Montes P, Guzmán E, Monge E. [Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome]. <i>Rev Gastroenterol Peru.</i> 2011;31:315-8.	Peru	TRANS
Jimenez-Gonzalez DE, Martinez-Flores WA, Reyes-Gordillo J, Ramirez-Miranda ME, Arroyo-Escalante S, Romero-Valdovinos M, Stark D, Souza-Saldivar V, Martinez-Hernandez F, Flisser A, Olivo-Diaz A, Maravilla P. Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population. <i>Parasitol Res.</i> 2012;110:1269-75.	Mexico	TRANS
Schmulson M. [Irritable bowel syndrome (IBS) in the 2012 DDW]. <i>Rev Gastroenterol Mex.</i> 2012;77.	Mexico	REV/ED
Schmulson M, Pulido-London D, Rodriguez O, Morales-Rochlin N, Martinez-García R, Gutierrez-Ruiz MC, López-Alvarenga JC, Robles-Díaz G, Gutiérrez-Reyes G. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. <i>Am J Gastroenterol.</i> 2012;107:747-53.	Mexico	TRANS
Schmulson M, Chey WD. Abnormal immune regulation and low-grade inflammation in IBS: does one size fit all? <i>Am J Gastroenterol.</i> 2012;107:273-5.	Mexico	REV/ED
Chacaltana Mendoza A, Díaz Ríos R, Alva Alva E, Vásquez Valverde N, Celestino Morales C. [Perception of pain during sigmoidoscopy flexible as an additional diagnostic method for irritable bowel syndrome]. <i>Rev Gastroenterol Peru.</i> 2012;32:178-83.	Peru	DX
Olivo-Díaz A, Romero-Valdovinos M, Gudiño-Ramírez A, Reyes-Gordillo J, Jimenez-Gonzalez DE, Ramirez-Miranda ME, Martinez-Flores WA, Martinez-Hernandez F, Flisser A, Maravilla P. Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis. <i>Parasitol Res.</i> 2012;111:487-91.	Mexico	TRANS

**Table 1** (Continued)

Article	Country	Category
Romero-Valdovinos M, Gudiño-Ramírez A, Reyes-Gordillo J, Martínez-Flores WA, Ramírez-Miranda ME, Maravilla P, Olivo-Díaz A. Interleukin-8 and -10 gene polymorphisms in irritable bowel syndrome. <i>Mol Biol Rep.</i> 2012;39:8837-43.	Mexico	TRANS
Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, Gutiérrez-Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. <i>Rev Gastroenterol Mex.</i> 2012;77:82-90.	Mexico	REV/ED
Dima G, Peralta D, Novillo A, Las J, Besasso H, Soifer L. [Predominance of constipation in subjects with hydrogen-consuming intestinal flora]. <i>Acta Gastroenterol Latinoam.</i> 2012;42:182-5.	Argentina	TRANS
Las J, Peralta D, Dima G, Novillo A, Besasso H, Soifer L. Comparison of abdominal bloating severity between Irritable Bowel Syndrome patients with high and low levels of breath hydrogen excretion in a lactulose breath test. <i>Rev Gastroenterol Mex.</i> 2012;77:53-7.	Argentina	REV/ED
Bravo JA, Julio-Pieper M, Forsythe P, Kunze W, Dinan TG, Bienenstock J, Cryan JF. Communication between gastrointestinal bacteria and the nervous system. <i>Curr Opin Pharmacol.</i> 2012;12:667-72.	Chile/Great Britain	REV/ED
Díaz Ferrer J, Parra V, Bendaña T, Montes P, Solorzano P. [Probiotic supplement ( <i>Lactobacillus acidophilus</i> and <i>bulgaricus</i> ) utility in the treatment of irritable bowel syndrome]. <i>Rev Gastroenterol Peru.</i> 2012;32:387-93.	Peru	TX
Gonzales Gamarra RG, Ruiz Sánchez JG, León Jiménez F, Cubas Benavides F, Díaz Vélez C. [Prevalence of irritable bowel syndrome in the adult population of the city of Chiclayo in 2011]. <i>Rev Gastroenterol Peru.</i> 2012 Oct-Dec;32(4):381-6.	Peru	EPI/QOL
López-Colombo A, Morgan D, Bravo-González D, Montiel-Jarquín A, Méndez-Martínez S, Schmulson M. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. <i>Gastroenterol Res Pract.</i> 2012;2012:606174.	Mexico	EPI/QOL
López-Alvarenga JC, Sobrino-Cossío S, Remes-Troche JM, Chiu-Ugalde J, Vargas-Romero JA, Schmulson M. Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100 mg plus simethicone 300 mg po bid. <i>Rev Gastroenterol Mex.</i> 2013;78:21-7.	Mexico	TX
Schmulson M, Pulido-London D, Rodríguez Ó, Morales-Rochlin N, Martínez-García R, Gutiérrez-Ruiz MC, López-Alvarenga JC, Gutiérrez-Reyes G. IL-10 and TNF-alpha polymorphisms in subjects with irritable bowel syndrome in Mexico. <i>Rev Esp Enferm Dig.</i> 2013;105:392-9.	Mexico	TRANS
Schmulson M. [Irritable Bowel Syndrome (IBS) in the 2013 DDW]. <i>Rev Gastroenterol Mex.</i> 2013;78 Suppl 1:34-6.	Mexico	REV/ED
Rodríguez-Fandiño O, Hernández-Ruiz J, López-Vidal Y, Charúa L, Bandeh-Moghaddam H, Minzoni A, Guzmán C, Schmulson M. Intestinal recruiting and activation profiles in peripheral blood mononuclear cells in response topathogen-associated molecular patterns stimulation in patients with IBS. <i>Neurogastroenterol Motil.</i> 2013;25:872-e699.	Mexico	TRANS
García Carrasco M, Mendoza Pinto C, López Colombo A, Méndez Martínez S, Andari Sawaya R, Muñoz Guarneros M, Vázquez De Lara L, Lescas Hernández M, Montiel Jarquín A, Ramos Álvarez G, Schmulson M. Irritable bowel syndrome-type symptoms in female patients with mild systemic lupus erythematosus: frequency, related factors and quality of life. <i>Neurogastroenterol Motil.</i> 2013;25:958-66.	Mexico	EPI/QOL
Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or <i>Saccharomyces boulardii</i> . <i>Arq Gastroenterol.</i> 2013;50:304-9.	Brazil	TX
Madrid-Silva AM, Defilippi-Caffri C, Landskron-Ramos G, Olguín-Herrera F, Reyes-Ponce A, Castro-Lara A, Larraín-Corp S, Martínez-Roje N, Cortés-Espinoza J. [The prevalence of irritable bowel symptoms in a population of shopping mall visitors in Santiago de Chile]. <i>Rev Gastroenterol Mex.</i> 2013;78:203-10.	Chile	REV/ED
Schmulson M, Bielsa MV, Carmona-Sánchez R, Hernández A, López-Colombo A, López Vidal Y, Peláez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. <i>Rev Gastroenterol Mex.</i> 2014;79:96-134.	Mexico	REV/ED

**Table 1** (Continued)

Article	Country	Category
Nair P, Okhuysen PC, Jiang ZD, Carlin LG, Belkind-Gerson J, Flores J, Paredes M, DuPont HL. Persistent abdominal symptoms in US adults after short-term stay in Mexico. <i>J Travel Med.</i> 2014;21:153-8.	USA/Mexico	REV/ED
Coss-Adame E, Rao SS. Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings. <i>Curr Gastroenterol Rep.</i> 2014;16:379.	Mexico/USA	REV/ED
Schmulson M, Corazziari E, Ghoshal UC, Myung SJ, Gerson CD, Quigley EM, Gwee KA, Sperber AD. A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders: a report of the Rome Foundation Working Team on cross-cultural, multinational research. <i>Neurogastroenterol Motil.</i> 2014;26:1368-85.	Multinational	REV/ED
Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H, Afifi AF, El-Khayat HR, Nouh A, Hassan MF, Fatah AA, Rucker Joerg I, Sánchez Núñez JM, Osthoff Rueda R, Jurkowska G, Walczak M, Malecka-Panas E, Linke K, Hartleb M, Janssen-van Solingen G. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. <i>Clin Drug Investig.</i> 2014;34:783-93.	Multinational	EPI/QOL
Ramírez-Cervantes K, Remes-Troche J, Del Pilar Milke-García M, Romero V, Uscanga LF. Characteristics and factors related to quality of life in Mexican Mestizo patients with celiac disease. <i>BMC Gastroenterol.</i> 2015;22:15:4.	Mexico	EPI/QOL
Vázquez-Frias R, Gutiérrez-Reyes G, Urbán-Reyes M, Velázquez-Guadarrama N, Fortoul-van der Goes TI, Reyes-López A, Consuelo-Sánchez A. Proinflammatory and anti-inflammatory cytokine profile in pediatric patients with irritable bowel syndrome. <i>Rev Gastroenterol Mex.</i> 2015.	Mexico	TRANS
Remes-Troche JM, Torres-Aguilera M, Montes-Martínez V, Jiménez-García VA, Roesch-Dietlen F. Prevalence of irritable bowel syndrome in caregivers of patients with chronic diseases. <i>Neurogastroenterol Motil.</i> 2015; [Epub ahead of print]	Mexico	EPI/QOL
Gerson CD, Gerson MJ, Chang L, Corazziari ES, Dumitrascu D, Ghoshal UC, Porcelli P, Schmulson M, Wang WA, Zali M. A cross-cultural investigation of attachment style, catastrophizing, negative pain beliefs, and symptom severity in irritable bowel syndrome. <i>Neurogastroenterol Motil.</i> 2015;27:490-500.	USA	EPI/QOL

In conclusion, there has been an important increase in articles on IBS in Mexico and Latin America over the past years, reflecting the ever-growing maturity in the region in this field, making it possible for us to have consensuses based on our own information. Additionally, in order to carry out adequate and unbiased systematic reviews, searches should also include local repositories.

## Financial disclosure

No financial support was received in relation to this study.

## Conflict of interest

The authors declare that there is no conflict of interest.

## References

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. *Clin Gastroenterol Hepatol.* 2012;10:712-21.
2. Soares RL, dos Santos JM, Rocha VR. Prevalence of irritable bowel syndrome in a Brazilian Amazon community. *Neurogastroenterol Motil.* 2005;17:883.
3. Schmulson M, López-Colombo A. Epidemiology of irritable bowel syndrome. In: Simren M, Törnblom H, eds. Clinical insights: Irritable bowel syndrome: Diagnosis and management. Cap. 1. London: Future Medicine Ltd.; 2013. p. 5-20.
4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. *Gastroenterology.* 2002;122:1500-11.
5. Iade B, Toma R. Frecuencia del síndrome de intestino irritable en una población de Montevideo. *Arch Med Int.* 2003;XXV: 91-6.
6. Veitia G, Pernalete B, Cachima L, et al. Prevalencia del síndrome intestino irritable en la población adulta venezolana. *Revista GEN.* 2013;67:139-44.
7. García-Mazcorro JF, Cruz-Valdés JC, Marroquín-Cardona AG, et al. Microbiota gastrointestinal y síndrome de intestino irritable. *Rev Gastroenterol Méx.* 2014;79:215-6.
8. Schmulson M, Saps M, Bashashati M. Abnormal immune regulation in children with irritable bowel syndrome. *Rev Gastroenterol Mex.* 2015;80:3-5.
9. Schmulson M, Chang L. The treatment of functional abdominal bloating and distension. *Aliment Pharmacol Ther.* 2011;33:1071-86.
10. Coss-Adame E, Rao SS. Brain and gut interactions in irritable bowel syndrome: New paradigms and new understandings. *Curr Gastroenterol Rep.* 2014;16:379.